Predicting long-term survival and cancer recurrence in patients with colorectal cancer is difficult because of the many factors that may affect the prognosis. This study investigated the prognostic significance of postoperative infections for patient outcome.
Methods
From an electronic database we selected 192 patients undergoing elective radical surgery for Dukes’ stage B and C colorectal adenocarcinoma. The five-year survival rates were analyzed by the Kaplan-Meier method. Univariate and multivariate analyses were carried out to evaluate the potential prognostic variables using the Cox proportional hazard model.
Results
Forty-three patients developed deep incisional or organ/space surgical site infections, while the remaining 149 were complication free. The two groups were comparable for baseline, surgical and histopathological characteristics. At univariate analysis, Dukes’ stage and infections were negative prognostic factors, while peritumoral infiltration of lymphocytes and eosinophils and fibrotic tissue appeared as protective variables. However, multivariate analysis showed that only Dukes’ stage (P = 0.048) and occurrence of postoperative infectious complications (P = 0.011) were independently associated with outcome. In patients with infectious complications, the survival rate was significantly lower than in patients without infections (log-rank = 0.0004).
Conclusions
The present results suggest the importance of evaluating other variables besides tumor stage in the prediction of long-term outcome. In prognostic studies more attention should be paid to postoperative infections.
MolifeR., LoriganP., MacNeilS.: Gender and survival in malignant tumours.Cancer Treat Rev, 27: 201–209, 2001.
4.
HodgsonD.C., FuchsC.S., AyanianJ.Z.: Impact of patient and provider characteristics on the treatment and outcome of colorectal cancer.J Natl Cancer Inst, 93: 501–515, 2001.
5.
ShafirM., BekesiG., PapatestasA., SlaterG., AufsesA.H.: Preoperative and postoperative immunological evaluation of patients with colorectal cancer.Cancer, 46: 700–705, 1980.
6.
HermanekP., HermanekP.J.: Role of the surgeon as a variable in the treatment of rectal cancer.Semin Surg Oncol, 19: 329–335, 2000.
7.
TurnbullR.B., KyleK., WatsonF.R., SprattJ.: Cancer of the colon.The influence of no touch isolation technique on survival rate. Ann Surg, 166: 420–427, 1967.
8.
SongF., GlennyA.M.: Antimicrobial prophylaxis in colorectal surgery: a systematic review of the randomized controlled trials.Br J Surg, 85: 1232–1241, 1998.
9.
HolzheimerR.G., HauptW., ThiedeA., SchwarkopfA.: The challenge of postoperative infections: does the surgeon make a difference?Infect Control Hosp Epidemiol, 18: 449–456, 1997.
10.
TayolE.W.: Surgical infections: current concerns.Eur J Surg, Suppl578: 5–9, 1997.
11.
BragaM., VignaliA., GianottiL., ZulianiW., RadaelliG., GruarinP.: Laparoscopic versus open colorectal surgery.A randomized clinical trial on short term outcome. Ann Surg, 236: 759–767, 2002.
12.
HalfstromL., HolminT.: Relationship between postoperative temperature and survival in patients resected for colorectal cancer.Am J Surg, 135: 312–314, 1978.
13.
DionigiR., DominioniL., CampaniM.: Infections in cancer patients.Surg Clin North Am, 60: 145–159, 1980.
14.
SensenigD.M., RossiN.P., EhrehalfJ.L.: Results of surgical treatment of bronchogenic carcinoma.Surg Gynecol Obstet, 116: 279–284, 1963.
Perez RuizL., GomezL., VinasJ., TorresS., AndreoniB.: Prognostic significance of postoperative septic complications in rectal cancer surgery.Minerva Chirurgica, 51: 447–450, 1996.
17.
WigmoreS.J., McMahonA.J., SturgeonC.M., FearonK.C.H.: Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer.Br J Surg, 88: 255–260, 2001.
18.
NowackiM.P., SzymenderaJ.J.: The strongest prognostic factors in colorectal carcinoma.Dis Colon Rectum, 26: 263–268, 1983.
19.
NozoeT., MatsumataT., KitamuraM., SugimachiK.: Significance of preoperative evaluation of serum C-reactive protein as an indicator of prognosis in colorectal cancer.Am J Surg, 176: 335–338, 1999.
20.
VartyP.P., LinehanI.P., BoulosP.B.: Intra abdominal sepsis and survival after surgery for colorectal cancer.Br J Surg, 81: 915–918, 1994.
21.
FuciniC., BandettiniL., D'EliaM., FilipponiF., Herd-SmithA.: Are postoperative fever and/or septic complications prognostic factors in colorectal cancer resection for cure?Dis Colon Rectum, 28: 94–95, 1985.
22.
DukesC.E.: The classification of cancer of the rectum.J Pathol Bacteriol, 35: 323–332, 1932.
23.
JassJ.R., LoveS.B., NorthoverJ.M.: A new prognostic classification of rectal cancer.Lancet, 1: 1303–1306, 1987.
24.
MangramA.J., HoranT.C., PearsonM.L., SilverL.C., JarvisW.R.: Guideline for prevention of surgical site infection, 1999.Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control, 27: 97–134, 1999.
25.
YarbroJ.W., PageD.L., FieldingL.P., PartridgeE.E., MurphyG.P.: American Joint Committee on Cancer prognostic factors consensus conference.Cancer, 86: 2436–2446, 1999.
26.
FalconerJ.S., FearonK.C.H., RossJ.A., EltonR., WigmoreS.J., GardenO.J.: Acute-phase protein response and survival in pancreatic cancer.Cancer, 75: 2077–2082, 1995.
27.
BlayJ.Y., NegrierS., CombaretV., AttaliS., GoillotE., MerroucheT.: Serum levels of interleukin 6 as a prognostic factor in metastatic renal cell carcinoma.Cancer Res, 52: 3317–3322, 1992.
28.
LegouffeE., RodriguezC., PicotM.C., RichardB., KleinB., RossiJ.F.: C-reactive protein serum levels in a valuable and simple prognostic marker in non Hodgkin's lymphoma.Leuk Lymphoma, 31: 351–357, 1998.
29.
AkyolA.M., McGregorJ.R., GallowayD.F., MurrayG.D., GeorgeW.D.: Anastomotic leaks in colorectal cancer surgery: a risk factor for recurrence.Int J Colorectal Dis, 6: 179–183, 1991.
30.
BellS.W., WalkerK.G., RickardMJFX: Anastomotic leakage after curative anterior resection results in a higher prevalence of local recurrence.Br J Surg, 90: 1261, 2003.
31.
KressnerU., GrafW., MahtemeH., PahlamnL., GlimeliusB.: Septic complications and prognosis after curative surgery for rectal cancer.Dis Colon Rectum, 45: 316, 2002.
32.
KillingbackM., BarronP., DentO.F.: Local recurrence after curative resection of cancer of the rectum without total mesorectal excision.Dis Colon Rectum, 44: 437, 2001.
33.
PetersenS., FreitagM., HellmichG., LudwigK.: Anastomotic leakage: impact on local recurrence and survival of colorectal cancer.Int J Colorectal Dis, 13: 160, 1998.
34.
HoferS.O.P., MolemaG., HermensRAEC, WaneboH.J., ReichnerJ.S., HoekstraH.J.: The effect of surgical wounding on tumour development.Eur J Surg Oncol, 25: 231–243, 1999.
35.
HoferS.O.P., ShrajerD., ReichnerJ.S., HoekstraH.J., WaneboH.J.: Wound-induced tumor progression.A possible role in tumor recurrence after tumor resction. Arch Surg, 133: 383–389, 1998.
36.
TsavellasG., PatelH., Allen-MershT.G.: Detection and clinical significance of occult tumour cells in colorectal cancer.Br J Surg, 88: 1307–1320, 2001.
37.
FongY., MoldawerL.L., DhiresG.Y., LowryS.F.: The biological characteristics of cytokines and their implication in surgical injury.Surg Gynecol Obstet, 170: 363–373, 1990.
38.
VolkH.D., ReinkeP., DockeW.D.: Clinical aspects: from systemic inflammation to immunoparalysis.Chem Immunol, 74: 162–177, 2000.
39.
Menetrier-CauxC., MontmainG., DieuM.C.: Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor.Blood, 92: 4778–4791, 1998.
40.
HornF., HenzeC., HeidrichK.: Interleukin-6 signal transduction and lymphocyte function.Immunobiology, 202: 151–167, 2000.
41.
BartonB.E.: IL-6-like cytokines and cancer cachexia: consequence of chronic inflammation.Immunol Res, 23: 41–58, 2001.
42.
SmithP.C., HobischA., LinD.L., KellerE.T.: Interleukin 6 and prostate cancer progression.Cytokine Growth Factor Rev, 12: 33–40, 2001.
43.
ZhouD., MunsterA.M., WinchurchR.A.: Inhibitory effects of interleukin-6 on immunity.Arch Surg, 127: 65–69, 1992.
44.
BrivioF., LissoniP., PeregoM.S., LissoniA., FumagalliL.: Abrogation of surgery-induced IL-6 hypersecretion by presurgical immunotherapy with IL-2 and its importance in the prevention of postoperative complications.J Biol Regul Homeost Agents, 15: 370–374, 2001.
45.
BrivioF., LissoniP., TisiE., ErbaL., BarniS., TanciniG.: Effect of a preoperative therapy with interleukin-2 on surgey-induced lymphocytopenia in cancer patients.Oncology, 49: 65–69, 1992.
